title: Multiple drug combinations with "low-dose" cyclosporin for renal transplantation. Multivariate analysis of risk factors determining short-term graft survival within one renal transplant center.
abstract: The factors affecting graft survival in transplant recipients receiving cyclosporin (CsA) are still being debated. Our report is based on an analysis of 202 successive transplantations performed in our institution from May 1984 to December 1986, using low-dose CsA as the basic means of immunosuppression. A total of 142 patients received the triple combination CsA, azathioprine (AZA), and corticosteroids. Sixty patients received a prophylactic combination of CsA, corticosteroids, and antilymphocyte globulins (ALG). From January to December 1986, both regimens were compared in a prospective randomized trial. The factors that affect graft survival were analyzed using the Cox multivariate hazard analysis. The relative risks were calculated for pretransplant baseline risk factors and for outcome-dependent post-transplant risk factors for surviving grafts at 1 month. Transplants performed with a prolonged ischemia time and patients whose graft did not function immediately were statistically at higher risk of graft loss. Adding prophylactic ALG to CsA was associated with better graft survival. Patients who experienced more than 1 rejection crisis and patients whose 1-month CsA dose was lower than or equal to 5 mg/kg per day were also at significantly higher risk of further graft loss. Neither HLA matching, peak panel reactivity, age of the recipient, occurrence of post-transplant renal dysfunction nor 1-month renal function affected the short-term graft outcome.
authors.affiliation: Service de Néphrologie, Hôpital de Bicêtre, Kremlin Bicêtre, France.
authors.forename: C
authors.initials: C
authors.lastname: Hiesse
authors.forename: P
authors.initials: P
authors.lastname: Prevost
authors.forename: M
authors.initials: M
authors.lastname: Busson
authors.forename: O
authors.initials: O
authors.lastname: Lantz
authors.forename: M
authors.initials: M
authors.lastname: Cantarovich
authors.forename: J
authors.initials: J
authors.lastname: Bellamy
authors.forename: G
authors.initials: G
authors.lastname: Benoit
authors.forename: B
authors.initials: B
authors.lastname: Charpentier
authors.forename: D
authors.initials: D
authors.lastname: Fries
mesh_terms: D000305:Adrenal Cortex Hormones / Q000008:administration & dosage; D000328:Adult; D000961:Antilymphocyte Serum / Q000008:administration & dosage; D001379:Azathioprine / Q000008:administration & dosage; D003524:Cyclosporins / Q000008:administration & dosage*; D004359:Drug Therapy, Combination; D005260:Female; D006085:Graft Survival; D006680:HLA Antigens; D006801:Humans; D016030:Kidney Transplantation; D008297:Male; D012307:Risk Factors
chemical_list: D000305:Adrenal Cortex Hormones; D000961:Antilymphocyte Serum; D003524:Cyclosporins; D006680:HLA Antigens; D001379:Azathioprine